Leqembi (Lecanemab)
Out of stock
We will notify you as soon as it becomes available.
-
Description
-
Related Products
-
Related Conditions
Fact Table
| Fact Table | |
|---|---|
| Formula | C6476H9996N1724O2010S44 (monoclonal antibody) |
| License | FDA approved (Accelerated Approval) |
| Bioavailability | Not available (IV administration) |
| Legal status | Prescription Drugs |
| Chemical Name | Lecanemab |
| Elimination half-life | Approximately 6-10 days |
| Dosage (Strength) | 200 mg or 500 mg vials, administered intravenously |
| Pregnancy | Not recommended (Category N/A) |
| Brands | Leqembi |
| Protein binding | High protein binding due to monoclonal antibody structure |
| PubChem CID | Not available |
| MedlinePlus | Not listed |
| ChEBI | Not available |
| ATC code | Not available |
| DrugBank | DB15175 (Lecanemab) |
| KEGG | D11964 (Lecanemab) |
| Routes of administration | Intravenous |
Leqembi is a medication designed to slow the progression of Alzheimer's disease in its early stages. Approved by the FDA, Leqembi offers hope to patients diagnosed with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. This medication targets and helps to clear out amyloid beta plaques, a hallmark of Alzheimer's, which are believed to play a crucial role in the degeneration of neurons in the brain.
Leqembi is specifically tailored for individuals who have confirmed accumulation of amyloid beta in their brains, which can be determined through imaging tests. The administration of Leqembi can potentially improve cognitive function, delay cognitive decline, and maintain independence for a longer period in the disease's progression. Before you buy Leqembi , it is crucial that you talk to your healthcare provider about potential side effects and Leqembi cost.
Directions
Leqembi dosage is administered as an intravenous infusion. It is crucial to follow the specific instructions provided by healthcare providers who will administer the medication in a clinical setting. Leqembi is administered as a bi-weekly infusion for the first three months. After the initial phase, the treatment frequency is usually adjusted based on patient response and tolerability.
Ingredients
Active Ingredient: Lecanemab
Cautions
Leqembi is not suitable for all patients with Alzheimer's disease; it is only indicated for those with mild cognitive impairment or mild dementia stages of the disease with confirmed amyloid pathology.
Before starting treatment, patients must undergo brain imaging to confirm the presence of amyloid plaques.
Regular monitoring of brain imaging is recommended to assess changes in amyloid levels and to monitor for potential side effects like amyloid-related imaging abnormalities (ARIA), which can include brain swelling or microhemorrhages.
Routine blood tests may be required to monitor for other potential side effects.
Interactions
Leqembi can interact with other medications, which may alter its effectiveness or increase the risk of side effects. It is important to discuss all medications, including over-the-counter drugs and supplements, with the healthcare provider. Possible Interactions include immunosuppressants, anti-inflammatory drugs and other medications for Alzheimer's disease.
Side Effects
Common side effects:
- Headache
- Fatigue
- Infusion-related reactions such as redness, itching, or swelling at the infusion site
- Nausea
Frequently Asked Questions about Leqembi (Lecanemab-irmb)
What is Leqembi used for?
Leqembi (lecanemab-irmb) is used to treat Alzheimer’s disease in adults who have mild cognitive impairment or mild dementia.
How does Leqembi work?
Leqembi works by reducing the amount of beta-amyloid plaques in the brain, which are thought to play a key role in Alzheimer’s disease.
How is Leqembi administered?
Leqembi is given as an intravenous (IV) infusion over approximately one hour, once every two weeks.
How long do you take Leqembi?
Leqembi is typically taken once every two weeks for as long as it is effective and side effects are manageable.
Is Leqembi effective?
Leqembi has shown some effectiveness in slowing cognitive decline in people with early Alzheimer’s disease, but it is not a cure.
What are the side effects of Leqembi?
Common side effects of Leqembi include headache, cough, diarrhea, and infusion-related reactions. Serious side effects can include brain swelling or small spots of bleeding in the brain.
Who should not take Lecanemab?
Lecanemab (Leqembi) is not recommended for people with full cognitive function or those in the later stages of Alzheimer’s disease.
How long does it take for Leqembi to work?
Leqembi starts to work after the first dose, but because of how the drug works, patients likely won’t feel the drug working in their body.
